NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/28/2026 13:25
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization321.05 mln
Float48.56 mln
Earnings Date08/12/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
6.67
Exceptional upside
Relative Strength
31
/ 100
Underperforming
Debt / Equity
0.19
Very low leverage
ROE
-50.81
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Zentalis Pharmaceuticals is a San Diego-based drug development company founded in 2014, working to bring new cancer treatments to patients across the United States. Its primary focus is azenosertib, a compound currently being tested in multiple clinical trials targeting ovarian cancer, other solid tumors, and cases where patients have stopped responding to existing therapies. The company also works alongside licensing and research partners to advance its pipeline.
